What does the research say about food noise and GLP-1 medications?

What is food noise?

Food noise is the persistent mental background chatter about food — cravings, planning, negotiation — that runs even when you're not hungry. It's linked to hunger-hormone signaling in the brain, not willpower.

It is not yet a formal medical diagnosis, but researchers are converging on a clinical definition. One published conceptual model describes food noise as heightened or persistent food-cue reactivity that leads to intrusive food-related thoughts and maladaptive eating.³ In other words, the brain over-responds to the sight, smell, or thought of food, and those cues turn into thoughts that are hard to switch off.

It is also common but under-recognized. Prior research found that roughly 57% of people living with overweight or obesity have experienced food noise — though few were familiar with the term itself.² Naming the experience is often the first step people take toward understanding it.

What does the survey research show?

The most-cited recent data comes from the INFORM survey, presented at the European Association for the Study of Diabetes (EASD) 2025 meeting in Vienna. It surveyed 550 people taking semaglutide for weight management, using a previously validated 22-question Food Noise Questionnaire.¹ The headline findings:

These numbers are striking, and they match what people on GLP-1 treatment describe in their own words. One important caveat belongs right here: this is self-reported survey data, in which participants recalled their experience before treatment and rated it during treatment. It documents a strong, consistent pattern — not a controlled measurement of cause and effect. The "What the research does NOT say" section below covers the limits in full.

What happens in the brain?

The biology is still being worked out, so the language here is deliberately cautious — every claim is a "may," not a "does."

GLP-1 receptors exist in regions of the brain tied to appetite and reward, not just in the gut. Research links semaglutide to changes in dopamine and glutamate signaling that may reduce the rewarding "pull" of highly palatable food. Some research suggests GLP-1 medications may reduce the motivational drive toward food (the "wanting") more than the pleasure of eating it (the "liking") — which fits what people describe: food still tastes good, they just stop thinking about it between meals.

It is worth being honest about the gaps. Whether and how these medications cross the blood-brain barrier is still debated, and the exact mechanism is not settled. Some of the EASD 2025 research on semaglutide and eating behavior — including the INFORM survey — was conducted with involvement from the medication's manufacturer, Novo Nordisk, and should be read with that context.²

Why does this matter beyond weight?

The same reward-pathway research that may explain food noise is being explored for other kinds of cravings, and that is an active scientific question rather than a settled finding. To be clear: WeightlessRx provides GLP-1 treatment for weight management only — nothing on this page should be read as a claim about treating anything else. For the underlying biology, see our complete guide to food noise and our complete guide to semaglutide.

What the research does NOT say

This is the most important section on the page. The food-noise findings are consistent and meaningful, but they are easy to overstate. Here is what the evidence does not support.

Handled honestly, these limits are not a weakness of the research — they are the reason it is credible. A strong, consistent self-reported signal is exactly that: a reason to keep studying, not a reason to make promises.

Frequently asked questions

Summary

• Food noise is persistent, intrusive thinking about food, linked to hunger-hormone signaling in the brain rather than willpower — and increasingly described with a research-based definition built on food-cue reactivity.³
• In the 2025 INFORM survey of 550 semaglutide users, the share reporting constant food-related thoughts fell from 62% to 16%, and daily-life disruption fell from 60% to 20%.¹
• Food noise is common but under-recognized: prior research found roughly 57% of people living with overweight or obesity have experienced it, though few knew the term.²
• GLP-1 medications may reduce food noise by acting on appetite and reward pathways in the brain, but the exact mechanism is not settled and the data is largely self-reported.
• The research does not prove the effect is universal, permanent, or causally established — and some of it involved the medication's manufacturer, which is important context.²

Safety & important information

GLP-1 medications are prescription drugs that should be taken only under the supervision of a licensed clinician. They carry risks including, but not limited to, thyroid C-cell tumors (including thyroid cancer) and medullary thyroid carcinoma (MTC), pancreatitis, gallbladder issues, and hypoglycemia. Tell your clinician if you experience a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath.

Treatment eligibility is determined only after a U.S.-licensed clinician in our third-party provider network reviews your intake and medical history. To go further, read the research on GLP-1s and biological aging, compare semaglutide vs. tirzepatide, or learn how WeightlessRx works.